WAVE Life Sciences
Wave Life Sciences Ltd is a clinical-stage genetic medicine company developing stereopure RNA therapeutics utilizing its proprietary PRISM platform. The company advances oligonucleotide therapies targeting genetic disorders including Duchenne muscular dystrophy (WVE-N531), Huntington's disease (WVE-003), alpha-1 antitrypsin deficiency (WVE-006), and obesity. Principal revenue is driven through research milestone payments, strategic development partnerships, and capital raises prior to commercial authorization. Core end markets serve pediatric neurology clinics, rare disease institutes, pulmonology centers, and genetic prescription patients globally. Wave Life Sciences holds an innovative position in the biopharmaceutical sector for stereopure oligonucleotide RNA drug engineering. The company is incorporated in Singapore, headquartered in Cambridge, Massachusetts, and its ordinary shares trade on the Nasdaq Global Market.
7 of the funds FundTelligence covers report a position in WAVE Life Sciences.
- Legal name
- WAVE Life Sciences Ltd
- Sector
- Health Care
- Country
- Singapore
- Funds holding it
- 7
- Exposure themes
- Genetic Medicine, Precision Medicine & Genomics, RNA Therapeutics
Funds holding WAVE Life Sciences
- Schroder ISF Healthcare Innovation — Schroders · 0.66 % (full portfolio disclosed, June 2026)
- BNP Health Care Innovators — BNP Paribas · 0.24 % (full portfolio disclosed, June 2026)
- BNP US Small Cap — BNP Paribas · 0.23 % (full portfolio disclosed, June 2026)
- BlackRock iShares NASDAQ US Biotechnology UCITS ETF — BlackRock · 0.04 % (full portfolio disclosed, October 2026)
- Handelsbanken Global SMB Index Criteria — Handelsbanken · 0.01 % (full portfolio disclosed, October 2026)
- DNB Global Enhanced Small Cap — DNB · 0.01 % (full portfolio disclosed, September 2026)
- KLP AksjeGlobal Small Cap Indeks — KLP · 0.01 % (partially disclosed portfolio, June 2026)